Author: Jartti, Tuomas; Smits, Hermelijn H.; Bønnelykke, Klaus; Bircan, Ozlem; Elenius, Varpu; Konradsen, Jon R.; Maggina, Paraskevi; Makrinioti, Heidi; Stokholm, Jakob; Hedlin, Gunilla; Papadopoulos, Nikolaos; Ruszczynski, Marek; Ryczaj, Klaudia; Schaub, Bianca; Schwarze, Jürgen; Skevaki, Chrysanthi; Stenberg-Hammar, Katarina; Feleszko, Wojciech
Title: Bronchiolitis needs a revisit: Distinguishing between virus entities and their treatments Document date: 2018_11_25
ID: 4svg09dt_34
Snippet: Palivizumab: Immunoprophylaxis with palivizumab, a humanized monoclonal antibody against the RSV F glycoprotein, decreases the risk of hospitalization due to severe RSV illness among preterm infants (72% reduction), those with chronic lung disease (65% reduction), and hemodynamically significant congenital heart disease (53% reduction). 60 Interestingly, palivizumab has effectively reduced recurrent wheezing following hospitalization due to RSV, .....
Document: Palivizumab: Immunoprophylaxis with palivizumab, a humanized monoclonal antibody against the RSV F glycoprotein, decreases the risk of hospitalization due to severe RSV illness among preterm infants (72% reduction), those with chronic lung disease (65% reduction), and hemodynamically significant congenital heart disease (53% reduction). 60 Interestingly, palivizumab has effectively reduced recurrent wheezing following hospitalization due to RSV, but not asthma. 70 Ribavirin: Convincing data supporting ribavirin treatment for severe RSV infection are lacking, and its toxicity remains a concern. Therefore, ribavirin is not recommended in the current U.S. guidelines. 71 New treatments: There are currently approximately 28 RSV vaccines and antibodies in preclinical development and another 17 in clinical development. 59
Search related documents:
Co phrase search for related documents- chronic lung disease and current guideline: 1
- chronic lung disease and heart disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- chronic lung disease and hospitalization risk: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23
- chronic lung disease and lung disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- chronic lung disease and monoclonal antibody: 1, 2, 3, 4
- chronic lung disease and new treatment: 1, 2, 3, 4, 5, 6, 7, 8, 9
- chronic lung disease and preterm infant: 1
- clinical development and current guideline: 1, 2, 3
- clinical development and heart disease: 1, 2, 3, 4, 5, 6
- clinical development and hospitalization risk: 1, 2, 3, 4, 5
- clinical development and lung disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
- clinical development and monoclonal antibody: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- clinical development and new treatment: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- clinical development and preclinical development: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- concern remain and heart disease: 1
- congenital heart disease and heart disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- congenital heart disease and hospitalization risk: 1, 2, 3
- congenital heart disease and lung disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- congenital heart disease and monoclonal antibody: 1, 2
Co phrase search for related documents, hyperlinks ordered by date